Literature DB >> 17505477

Expression of mutated huntingtin fragment in the putamen is sufficient to produce abnormal movement in non-human primates.

Stéphane Palfi1, Emmanuel Brouillet, Béchir Jarraya, Jocelyne Bloch, Caroline Jan, Masahiro Shin, Françoise Condé, Xiao-Jiang Li, Patrick Aebischer, Philippe Hantraye, Nicole Déglon.   

Abstract

Huntington's disease (HD) is a neurological disorder characterized by striatal degeneration, motor symptoms and complex neuropsychiatric alterations. There is currently no genetic model of HD in non-human primates (NHPs). In this study we investigated neuropathological and behavioral changes following injections of lentiviral vectors encoding a fragment of mutated huntingtin (Htt171-82Q) into the dorsolateral sensorimotor putamen of macaques. In the first study, we injected Htt171-82Q into one hemisphere and a lentiviral vector encoding Htt171-19Q or saline into the other, and studied the animals for 9 weeks. During this period, when apomorphine was administered into Htt171-19Q/82Q animals, it induced progressive chorea, dystonia and ipsilateral turning behavior, whereas animals infected with Htt171-19Q/19Q showed no abnormal behavior. After 9 weeks, the putamen of animals infected with Htt171-82Q presented neuritic and nuclear Htt aggregates, reactive astrocytes and loss of the neuronal marker NeuN. In a second study, we injected Htt171-82Q bilaterally into the dorsolateral putamen. From week 15 after infection, these animals progressively developed spontaneous dyskinesia of the legs, arms, and trunk and, in one case, tics that persisted for up to 30 weeks. The present study constitutes a proof-of-principle for the development of a genetic model of HD in NHP.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17505477     DOI: 10.1038/sj.mt.6300185

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  25 in total

Review 1.  Antioxidants in Huntington's disease.

Authors:  Ashu Johri; M Flint Beal
Journal:  Biochim Biophys Acta       Date:  2011-11-23

Review 2.  Progress and prospects for genetic modification of nonhuman primate models in biomedical research.

Authors:  Anthony W S Chan
Journal:  ILAR J       Date:  2013

Review 3.  Gene therapy in mouse models of huntington disease.

Authors:  Amber L Southwell; Paul H Patterson
Journal:  Neuroscientist       Date:  2011-04       Impact factor: 7.519

4.  Lack of RAN-mediated toxicity in Huntington's disease knock-in mice.

Authors:  Su Yang; Huiming Yang; Luoxiu Huang; Luxiao Chen; Zhaohui Qin; Shihua Li; Xiao-Jiang Li
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-06       Impact factor: 11.205

5.  CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease.

Authors:  Su Yang; Renbao Chang; Huiming Yang; Ting Zhao; Yan Hong; Ha Eun Kong; Xiaobo Sun; Zhaohui Qin; Peng Jin; Shihua Li; Xiao-Jiang Li
Journal:  J Clin Invest       Date:  2017-06-19       Impact factor: 14.808

Review 6.  Choosing an animal model for the study of Huntington's disease.

Authors:  Mahmoud A Pouladi; A Jennifer Morton; Michael R Hayden
Journal:  Nat Rev Neurosci       Date:  2013-10       Impact factor: 34.870

7.  Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease.

Authors:  Jodi L McBride; Mark R Pitzer; Ryan L Boudreau; Brett Dufour; Theodore Hobbs; Sergio R Ojeda; Beverly L Davidson
Journal:  Mol Ther       Date:  2011-10-25       Impact factor: 11.454

Review 8.  Large animal models of neurological disorders for gene therapy.

Authors:  Christine Gagliardi; Bruce A Bunnell
Journal:  ILAR J       Date:  2009

9.  AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease.

Authors:  Nicholas R Franich; Helen L Fitzsimons; Dahna M Fong; Matthias Klugmann; Matthew J During; Deborah Young
Journal:  Mol Ther       Date:  2008-03-25       Impact factor: 11.454

10.  Stereotaxic Surgical Targeting of the Nonhuman Primate Caudate and Putamen: Gene Therapy for Huntington's Disease.

Authors:  Jodi L McBride; Randall L Clark
Journal:  Methods Mol Biol       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.